AbbVie Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABBV research report →
About the company
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients.
- CEO
- Robert A. Michael
- IPO
- 2013
- Employees
- 55,000
- HQ
- North Chicago, IL, US
Price Chart
- Market Cap
- $387.65B
- P/E
- 107.14
- P/S
- 6.18
- P/B
- 14.18
- EV/EBITDA
- 26.70
- Div Yield
- 3.07%
- Gross Margin
- 70.68%
- Op Margin
- 27.60%
- Net Margin
- 5.79%
- ROE
- 68.01%
- ROIC
- 10.29%
- Revenue
- $61.16B · 8.57%
- Net Income
- $4.23B · -1.22%
- EPS
- $2.37 · -1.25%
- Op Income
- $20.09B
- FCF YoY
- -0.09%
- 52W High
- $244.81
- 52W Low
- $181.73
- 50D MA
- $211.67
- 200D MA
- $220.54
- Beta
- 0.31
- Avg Volume
- 6.42M
Get TickerSpark's AI analysis on ABBV
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 8, 26 | FALK THOMAS J | other | 1,118 |
| May 8, 26 | WADDELL FREDERICK H | other | 1,118 |
| May 8, 26 | Roberts Rebecca B | other | 1,118 |
| May 8, 26 | RAPP EDWARD J | other | 1,118 |
| May 8, 26 | Quaggin Susan E | other | 1,118 |
| May 8, 26 | MEYER MELODY B | other | 1,118 |
| May 8, 26 | Hart Brett J | other | 1,118 |
| May 8, 26 | FREYMAN THOMAS C | other | 1,118 |
| May 8, 26 | Davis Jennifer L. | other | 1,118 |
| May 8, 26 | BURNSIDE WILLIAM H.L. | other | 1,118 |
Our ABBV coverage
Recent articles, reports, and earnings notes.
Want a deeper read on ABBV?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.